Xeljanz®/Xeljanz® XR (tofacitinib) – New indication
December 14, 2017 – Pfizer announced the FDA approval of Xeljanz/Xeljanz XR (tofacitinib) for the treatment of adult patients with active psoriatic arthritis (PsA) who have had an inadequate response or intolerance to methotrexate or other disease-modifying antirheumatic drugs (DMARDs).
Top